Showing 181 - 200 results of 506 for search '"combination therapy"', query time: 0.06s Refine Results
  1. 181

    Pulmonary Nocardiosis: Review of Cases and an Update by Malini Shariff, Jayanthi Gunasekaran

    Published 2016-01-01
    “…Patients with disseminated or severe nocardiosis should be treated with combination therapy with two or more active agents.…”
    Get full text
    Article
  2. 182

    Disseminated Abdominal Hydatidosis: A Rare Presentation of Common Infectious Disease by Abdulrahman Almalik, Aynaa Alsharidi, Mohammed Al-Sheef, Mushirah Enani

    Published 2014-01-01
    “…Significant symptomatic relief was achieved within the first two months of combination therapy with albendazole and praziquantel. HD is still of public health concern in the Middle East that needs optimized care.…”
    Get full text
    Article
  3. 183

    Therapeutic Potential of Combined 5% Lifitegrast and Tocopherol Eye Drops in Managing Inflammation and Oxidative Stress in Murine Dry Eye by Jayoung Moon, Enying Jiang, Jingting Liu, Hui Jin, Hee Su Yoon, Hoon-In Choi, Ji Suk Choi, Hong Qi, Hyeon-Jeong Yoon, Kyung Chul Yoon

    Published 2025-01-01
    “…<b>Conclusions:</b> Combined 5% LF and TCP eye drops improved tear film parameters and reduced inflammatory and oxidative stress markers. The combination therapy can mitigate ocular surface damage by managing inflammation and oxidative stress in dry eye.…”
    Get full text
    Article
  4. 184

    SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase by Xiaobin Wang, Shulin Li, Zichen Li, Zhuona Lin, Zhifeng Wang

    Published 2025-01-01
    “…Despite significant advances in diagnosis and treatment, the compromised therapeutic effect of chemotherapeutic agents, such as Oxaliplatin (OXA), remains a major clinical challenge. Thus, a combination therapy is required to enhance the OXA’s therapeutic effectiveness and improve patient outcomes. …”
    Get full text
    Article
  5. 185

    NIR‐II emissive biohybrid nanovesicles as mild‐temperature photothermal antibiofilm agents against acute bacterial skin and skin‐structure infections by Ji Wang, Zhihao Wu, Xiaoxi Ma, Zhihui Huang, Haorong Dong, Jinxin Zhang, Xiaoming Liu, Pengfei Zhang, Shuhuai Yao

    Published 2025-01-01
    “…The new combination therapy demonstrated significant improvement in treating severe Staphylococcus aureus infections caused by biofilms in vitro and in vivo, presenting a promising alternative to traditional antibiotic therapy.…”
    Get full text
    Article
  6. 186
  7. 187

    TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC by Xiao-Mei Tang, Min-Min Shi, Jia-Cheng Wang, Yi-Jin Gu, Yu-Ting Dai, Qin-Xin Yang, Jia Liu, Ling-Jie Ren, Xin-Yun Liu, Chun Yang, Fang-Fang Ma, Ji-Bing Liu, Hong Yu, Da Fu, Yun-Feng Wang

    Published 2025-02-01
    “…In conclusion, TOPBP1 is a potential marker for optimizing the olaparib and AZD6738 combination therapy in PDAC. This study highlights the clinical significance of TOPBP1 in the treatment of PDAC and emphasizes the potential implications for a broader population of patients.…”
    Get full text
    Article
  8. 188

    Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors by Linan Yin, Ruibao Liu, Wei Li, Shijie Li, Xunbo Hou

    Published 2025-01-01
    “…Methods This retrospective study included 172 patients with uHCC who underwent combination therapy of TACE-HAIC with TKIs and PD-1 inhibitors. …”
    Get full text
    Article
  9. 189
  10. 190

    Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Ph... by Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F

    Published 2025-02-01
    “…Chemotherapy-free option lenvatinib plus anti-programmed cell death protein-1 (PD-1) combination therapy has shown promising results in several malignancies including ovarian cancer, but the toxicity of a high starting dose of lenvatinib is also notable and needs to be improved. …”
    Get full text
    Article
  11. 191

    A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer by Shuailei Dong, Chen Wei, Xueting Wang, Xinyi Yang, Wei Shen, Shuyi Li, Jiye Xu, Yijie Ma, Liangyu Bie, Wenyue Yu, Ning Li

    Published 2025-01-01
    “…The median PFS was significantly longer in the combination-therapy (CT) group than in the MT group (5.3 versus 3.8 months, HR: 0.51, 95% CI: 0.31–0.85, p = 0.010), and the median OS was also notably increased (10.0 versus 6.8 months, HR: 0.45, 95% CI: 0.27–0.77, p = 0.003). …”
    Get full text
    Article
  12. 192

    Treatment of a schizophrenia patient on long-term super-dose antipsychotics: a case report by Xiaobo Xie, Jinzhang Chen, Hongli Song, Zebin Fan

    Published 2025-01-01
    “…The patient was followed for four years, during which his psychiatric symptoms remained under partial control.ConclusionClinicians must consider individual differences in the efficacy and adverse effects of antipsychotics and weigh the benefits and risks of combination therapy. Future efforts should focus on strengthening health education for patients with schizophrenia and their families to improve treatment compliance and outcomes.…”
    Get full text
    Article
  13. 193

    Overcoming immune evasion with innovative multi-target approaches for glioblastoma by Hai Su, Yin Peng, Yilong Wu, Xiaoli Zeng, Xiaoli Zeng, Xiaoli Zeng

    Published 2025-01-01
    “…This review explores glioblastoma’s immune evasion mechanisms, the role of ICIs in the tumor microenvironment, and recent clinical advancements, offering theoretical insights and directions for monotherapy and combination therapy in glioblastoma management.…”
    Get full text
    Article
  14. 194

    Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation by Esin Oktay, Özlem Yersal, Nezih Meydan, Mehmet Sağıroğlu, Ömer Uyanık, Sabri Barutca

    Published 2013-01-01
    “…Trastuzumab treatment does not prevent intracranial seeding and is largely ineffective for established central nervous system metastasis in HER2 overexpressing breast cancer patients. Combination therapy of lapatinib and capecitabine may be an effective treatment option for brain metastasis of HER2-positive breast cancer. …”
    Get full text
    Article
  15. 195

    Ischemic Colitis During Pegylated Interferon-Alpha and Ribavirin Therapy for Chronic Hepatitis C by Yvette Leung, Stefan J Urbanski, Lynn Schindel, Robert P Myers

    Published 2006-01-01
    “…The present study describes the first case of ischemic colitis attributable to pegylated IFN-α and ribavirin combination therapy in an HCV-infected patient after 34 weeks of treatment. …”
    Get full text
    Article
  16. 196

    Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherap... by Cheng-Wei Huang, Ruo-Han Tseng

    Published 2024-01-01
    “…Herein, we report a patient with ovarian clear-cell carcinoma refractory to platinum-based chemotherapy, who was treated with a reduced dose of bevacizumab and pembrolizumab combination therapy and achieved a complete treatment response.…”
    Get full text
    Article
  17. 197

    Reproductive Late Effects in Female Survivors of Childhood Cancer by Shivany Gnaneswaran, Rebecca Deans, Richard J. Cohn

    Published 2012-01-01
    “…Patients who receive chemotherapy and/or ovarian radiation are at risk of premature ovarian failure; the risk increases with increasing radiation dose, alkylating agent score, combination therapy, and older age at treatment. Ovarian reserve may be assessed using antimullerian hormone assay and ultrasound measurements of ovarian volume and antral follicle count; however, their efficacy is poorly established in this cohort. …”
    Get full text
    Article
  18. 198

    Strategies to Overcome Antileishmanial Drugs Unresponsiveness by Shyam Sundar, Anup Singh, Om Prakash Singh

    Published 2014-01-01
    “…In the current review, we highlight various steps which could be implemented to halt the increasing unresponsiveness of drugs such as monitoring of therapy in the form of rational dosing and duration of treatment, understanding the mechanism of action of the drugs and drug resistance, identification of markers of resistance, distribution of drugs free of cost, evolution of effective combination therapy and immunotherapy, and proper management of HIV/VL coinfection and post-kala-azar dermal leishmaniasis (PKDL). …”
    Get full text
    Article
  19. 199

    Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat by Tamara Zenz, Robert Jenke, Denys Oliinyk, Sandra Noske, René Thieme, Tim Kahl, Ines Gockel, Florian Meier-Rosar, Achim Aigner, Thomas RH Büch

    Published 2025-02-01
    “…Moreover, our results provided the basis for combined entinostat + EGFR inhibitor (erlotinib) treatment, and indeed we demonstrate synergistic effects in combination therapy studies. Conclusion: Our findings establish the profound upregulation of the EGFR/AREG axis by entinostat as starting point for a rational combination therapy in gastric carcinoma.…”
    Get full text
    Article
  20. 200

    Differences in the Treatment Response to Antithyroid Drugs versus Electroconvulsive Therapy in a Case of Recurrent Catatonia due to Graves’ Disease by Takahiro Saito, Rie Saito, Hiroshi Suwa, Fumiatsu Yakushiji, Kenji Takezawa, Mitsuru Nakamura

    Published 2012-01-01
    “…The patient showed different treatment response in each episodes; in the first episode, psychiatric and physical symptoms were resolved by a combination of antithyroid and anxiolytic therapies, while in the second episode, the combination therapy did not ameliorate her symptoms and ECT was indicated. …”
    Get full text
    Article